<DOC>
	<DOC>NCT01567358</DOC>
	<brief_summary>The purpose of this study is to compare the safety of NI-071 with Remicade® (infliximab) in patients with Rheumatoid Arthritis inadequately treated with Methotrexate.</brief_summary>
	<brief_title>Study of NI-071 in Comparison With Remicade in Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1. Diagnosis of Rheumatoid Arthritis (RA) as defined by the 1987 revised American College of Rheumatology (ACR) criteria with ACR Functional Classification class IIII and disease duration of no less than 3 months 2. Patients must receive a minimum of 3 months treatment with methotrexate (MTX) (≥ 6 mg/week) prior to the Screening Visit. Patients must be on a stable dose of MTX (6 mg~16 mg mg/week) for a minimum of 4 weeks prior to the Screening Visit 1. History of following diseases Other Connective tissue disorders with joint symptom which may interfere the efficacy assessment Chlonic or recurrent infectious disease（bronchial ectasia, sinus inflammation etc.） Severe infectious disease（hepatitis, pneumonia、sepsis） History of demyelinating disease or multiple sclerosis Congestive heart failure lymphoproliferative disorder or myelodysplastic syndrome History of malignancy Interstitial lung disease 2. Patients with active or latent tuberculosis or history of tuberculosis</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>